- Home
- NMIH vs VRDN Comparison
NMIH vs VRDN Comparison
Compare NMIH & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | VRDN |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMIH | VRDN |
|---|---|---|
| Price | $37.51 | $32.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $41.20 | $39.00 |
| AVG Volume (30 Days) | 408.3K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.56 | N/A |
| EPS | ★ 4.79 | N/A |
| Revenue | ★ $692,208,000.00 | $70,789,000.00 |
| Revenue This Year | N/A | $26,477.48 |
| Revenue Next Year | $4.79 | $6.23 |
| P/E Ratio | $7.85 | ★ N/A |
| Revenue Growth | 8.86 | ★ 23340.07 |
| 52 Week Low | $31.90 | $9.90 |
| 52 Week High | $43.20 | $33.34 |
Technical Indicators
Market Signals| Indicator | NMIH | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 65.86 |
| Support Level | $37.91 | $30.22 |
| Resistance Level | $38.90 | $33.49 |
| Average True Range (ATR) | 0.70 | 1.20 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 41.45 | 74.81 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).